| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 24 | 2025 | 125 | 9.250 |
Why?
|
| Arthroplasty, Replacement, Hip | 16 | 2024 | 73 | 5.220 |
Why?
|
| Osteoarthritis, Knee | 16 | 2025 | 385 | 4.690 |
Why?
|
| Osteoarthritis, Hip | 8 | 2024 | 25 | 2.870 |
Why?
|
| Pain, Postoperative | 7 | 2025 | 161 | 2.350 |
Why?
|
| Hip Prosthesis | 13 | 2018 | 22 | 2.020 |
Why?
|
| Arthroplasty, Replacement | 5 | 2014 | 16 | 1.980 |
Why?
|
| Treatment Outcome | 32 | 2025 | 5584 | 1.710 |
Why?
|
| Pain Measurement | 10 | 2025 | 343 | 1.640 |
Why?
|
| Knee Joint | 11 | 2025 | 291 | 1.610 |
Why?
|
| Arthralgia | 4 | 2015 | 56 | 1.490 |
Why?
|
| Orthopedic Procedures | 5 | 2019 | 47 | 1.420 |
Why?
|
| Registries | 8 | 2015 | 872 | 1.410 |
Why?
|
| Orthopedics | 6 | 2019 | 29 | 1.360 |
Why?
|
| Patient Reported Outcome Measures | 7 | 2025 | 146 | 1.300 |
Why?
|
| Quality of Life | 6 | 2024 | 1221 | 1.290 |
Why?
|
| Activities of Daily Living | 5 | 2025 | 294 | 1.270 |
Why?
|
| Recovery of Function | 8 | 2025 | 283 | 1.250 |
Why?
|
| Prosthesis Failure | 14 | 2015 | 73 | 1.250 |
Why?
|
| Bone Cements | 9 | 2004 | 16 | 1.240 |
Why?
|
| Patient Satisfaction | 8 | 2024 | 431 | 1.200 |
Why?
|
| Disability Evaluation | 5 | 2015 | 214 | 1.090 |
Why?
|
| Patient Outcome Assessment | 3 | 2017 | 53 | 1.090 |
Why?
|
| Quality Indicators, Health Care | 3 | 2013 | 334 | 1.030 |
Why?
|
| Titanium | 7 | 2019 | 60 | 0.930 |
Why?
|
| Aged | 30 | 2025 | 14249 | 0.900 |
Why?
|
| Humans | 74 | 2025 | 62651 | 0.890 |
Why?
|
| Patient Selection | 3 | 2015 | 482 | 0.870 |
Why?
|
| Prospective Studies | 11 | 2024 | 3258 | 0.780 |
Why?
|
| Robotic Surgical Procedures | 1 | 2025 | 141 | 0.770 |
Why?
|
| Osteoarthritis | 4 | 2021 | 140 | 0.730 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 11 | 0.720 |
Why?
|
| Polyethylene | 4 | 2018 | 10 | 0.720 |
Why?
|
| Talus | 1 | 2020 | 1 | 0.710 |
Why?
|
| Retinal Detachment | 1 | 2021 | 18 | 0.710 |
Why?
|
| Osteonecrosis | 1 | 2020 | 7 | 0.710 |
Why?
|
| Polyethylenes | 3 | 2015 | 6 | 0.690 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 48 | 0.680 |
Why?
|
| Middle Aged | 25 | 2025 | 17358 | 0.620 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 707 | 0.620 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 15 | 0.610 |
Why?
|
| Femur | 6 | 2014 | 53 | 0.610 |
Why?
|
| Tantalum | 2 | 2015 | 5 | 0.600 |
Why?
|
| Metal-on-Metal Joint Prostheses | 1 | 2018 | 1 | 0.600 |
Why?
|
| Critical Pathways | 1 | 2018 | 32 | 0.590 |
Why?
|
| Bone Morphogenetic Protein 2 | 8 | 2017 | 48 | 0.580 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 33 | 0.580 |
Why?
|
| Perioperative Care | 2 | 2018 | 85 | 0.580 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 2445 | 0.570 |
Why?
|
| Hip Fractures | 1 | 2018 | 77 | 0.550 |
Why?
|
| Male | 33 | 2025 | 29469 | 0.530 |
Why?
|
| Radiostereometric Analysis | 2 | 2015 | 2 | 0.510 |
Why?
|
| Biocompatible Materials | 6 | 2019 | 148 | 0.510 |
Why?
|
| Risk Adjustment | 2 | 2017 | 94 | 0.490 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 2646 | 0.490 |
Why?
|
| Female | 29 | 2025 | 32478 | 0.490 |
Why?
|
| Patient Care Team | 1 | 2018 | 336 | 0.490 |
Why?
|
| Knee Prosthesis | 4 | 2001 | 10 | 0.480 |
Why?
|
| United States | 10 | 2025 | 7721 | 0.480 |
Why?
|
| Vancomycin | 4 | 2023 | 38 | 0.460 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 42 | 0.460 |
Why?
|
| Musculoskeletal Diseases | 1 | 2015 | 103 | 0.460 |
Why?
|
| Postoperative Complications | 8 | 2025 | 1284 | 0.450 |
Why?
|
| Coated Materials, Biocompatible | 4 | 2019 | 46 | 0.450 |
Why?
|
| Femoral Fractures | 6 | 2015 | 21 | 0.450 |
Why?
|
| Workload | 1 | 2015 | 121 | 0.440 |
Why?
|
| Osteogenesis | 10 | 2019 | 146 | 0.430 |
Why?
|
| Models, Psychological | 1 | 2013 | 97 | 0.420 |
Why?
|
| Quality Improvement | 2 | 2018 | 433 | 0.420 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 265 | 0.420 |
Why?
|
| Postoperative Care | 3 | 2010 | 120 | 0.410 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 194 | 0.410 |
Why?
|
| Information Dissemination | 1 | 2013 | 115 | 0.390 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 49 | 0.390 |
Why?
|
| Low Back Pain | 1 | 2013 | 114 | 0.390 |
Why?
|
| Bone Substitutes | 4 | 2014 | 16 | 0.390 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 832 | 0.390 |
Why?
|
| Chondrocytes | 4 | 2016 | 42 | 0.380 |
Why?
|
| Surgeons | 1 | 2015 | 180 | 0.380 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 120 | 0.380 |
Why?
|
| Tibia | 3 | 2020 | 70 | 0.380 |
Why?
|
| Schools, Medical | 1 | 2012 | 145 | 0.370 |
Why?
|
| Femur Head | 2 | 2009 | 3 | 0.360 |
Why?
|
| Emotions | 1 | 2013 | 223 | 0.360 |
Why?
|
| Osteolysis | 4 | 2010 | 17 | 0.350 |
Why?
|
| Cartilage, Articular | 3 | 2017 | 76 | 0.350 |
Why?
|
| Range of Motion, Articular | 2 | 2008 | 100 | 0.350 |
Why?
|
| Patient Readmission | 1 | 2015 | 429 | 0.350 |
Why?
|
| Bone and Bones | 4 | 2015 | 142 | 0.340 |
Why?
|
| Mental Health | 1 | 2013 | 363 | 0.340 |
Why?
|
| Staphylococcal Infections | 2 | 2023 | 129 | 0.340 |
Why?
|
| Cementation | 3 | 2004 | 3 | 0.340 |
Why?
|
| Narcotics | 1 | 2010 | 58 | 0.330 |
Why?
|
| Tissue Scaffolds | 4 | 2019 | 86 | 0.330 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 414 | 0.320 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 252 | 0.320 |
Why?
|
| Walking | 2 | 2008 | 238 | 0.310 |
Why?
|
| Preoperative Care | 1 | 2010 | 188 | 0.310 |
Why?
|
| Cohort Studies | 4 | 2024 | 2537 | 0.310 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 458 | 0.310 |
Why?
|
| Awards and Prizes | 2 | 2025 | 34 | 0.300 |
Why?
|
| Health Services Research | 3 | 2013 | 270 | 0.290 |
Why?
|
| Prosthesis Design | 8 | 2015 | 223 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 785 | 0.280 |
Why?
|
| Biomechanical Phenomena | 7 | 2015 | 269 | 0.280 |
Why?
|
| Fracture Healing | 3 | 2014 | 27 | 0.270 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1077 | 0.270 |
Why?
|
| Time Factors | 9 | 2015 | 3740 | 0.270 |
Why?
|
| Prostheses and Implants | 2 | 2019 | 71 | 0.260 |
Why?
|
| Pain | 2 | 2022 | 406 | 0.260 |
Why?
|
| Monitoring, Ambulatory | 1 | 2006 | 57 | 0.250 |
Why?
|
| Transforming Growth Factor beta | 4 | 2015 | 172 | 0.240 |
Why?
|
| Exercise Therapy | 1 | 2006 | 104 | 0.240 |
Why?
|
| Documentation | 1 | 2006 | 127 | 0.240 |
Why?
|
| Elective Surgical Procedures | 2 | 2017 | 117 | 0.240 |
Why?
|
| Aged, 80 and over | 10 | 2017 | 5403 | 0.240 |
Why?
|
| Preoperative Period | 2 | 2016 | 69 | 0.230 |
Why?
|
| Operative Time | 1 | 2025 | 91 | 0.230 |
Why?
|
| Adhesiveness | 1 | 2004 | 13 | 0.230 |
Why?
|
| Hydroxyapatites | 2 | 2014 | 8 | 0.220 |
Why?
|
| Polymethacrylic Acids | 2 | 2014 | 10 | 0.220 |
Why?
|
| Patient Compliance | 1 | 2006 | 358 | 0.220 |
Why?
|
| Metals | 2 | 2018 | 65 | 0.220 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2017 | 16 | 0.220 |
Why?
|
| Prevalence | 2 | 2022 | 1345 | 0.210 |
Why?
|
| Stress, Mechanical | 5 | 2005 | 112 | 0.200 |
Why?
|
| Back Pain | 1 | 2023 | 50 | 0.200 |
Why?
|
| Bone Transplantation | 2 | 2014 | 29 | 0.200 |
Why?
|
| Rats | 9 | 2023 | 1977 | 0.200 |
Why?
|
| Durapatite | 2 | 2015 | 29 | 0.200 |
Why?
|
| Recombinant Proteins | 7 | 2017 | 700 | 0.190 |
Why?
|
| Staphylococcus aureus | 2 | 2023 | 177 | 0.190 |
Why?
|
| Bone Regeneration | 2 | 2019 | 17 | 0.190 |
Why?
|
| Length of Stay | 1 | 2025 | 804 | 0.180 |
Why?
|
| Arthritis | 2 | 2021 | 53 | 0.180 |
Why?
|
| Sex Factors | 1 | 2024 | 972 | 0.180 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2019 | 62 | 0.180 |
Why?
|
| Adult | 9 | 2015 | 16620 | 0.170 |
Why?
|
| Ossification, Heterotopic | 3 | 1991 | 13 | 0.170 |
Why?
|
| Cell Differentiation | 9 | 2017 | 1346 | 0.170 |
Why?
|
| Menisci, Tibial | 2 | 2017 | 24 | 0.160 |
Why?
|
| Weight-Bearing | 4 | 2005 | 36 | 0.160 |
Why?
|
| Animals | 22 | 2023 | 20576 | 0.160 |
Why?
|
| Medicare | 1 | 2024 | 614 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2017 | 85 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 173 | 0.160 |
Why?
|
| Reoperation | 4 | 2012 | 290 | 0.160 |
Why?
|
| Osteoblasts | 3 | 2009 | 198 | 0.160 |
Why?
|
| Tranexamic Acid | 1 | 2018 | 6 | 0.150 |
Why?
|
| Denmark | 1 | 2018 | 17 | 0.150 |
Why?
|
| Surface Properties | 6 | 2014 | 278 | 0.150 |
Why?
|
| Materials Testing | 4 | 2004 | 83 | 0.150 |
Why?
|
| Cadaver | 5 | 2005 | 125 | 0.150 |
Why?
|
| Workflow | 1 | 2018 | 68 | 0.140 |
Why?
|
| Biofilms | 1 | 2019 | 81 | 0.140 |
Why?
|
| Physical Examination | 2 | 2016 | 112 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2018 | 158 | 0.140 |
Why?
|
| Tensile Strength | 3 | 2004 | 29 | 0.140 |
Why?
|
| Musculoskeletal Pain | 1 | 2017 | 28 | 0.140 |
Why?
|
| Bone Marrow Cells | 4 | 2015 | 237 | 0.130 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 46 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2009 | 152 | 0.130 |
Why?
|
| Radiography | 6 | 2009 | 535 | 0.130 |
Why?
|
| Aging | 3 | 2017 | 740 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 97 | 0.130 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1995 | 6 | 0.120 |
Why?
|
| Mice | 12 | 2023 | 10802 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2004 | 608 | 0.120 |
Why?
|
| Consensus | 1 | 2016 | 225 | 0.120 |
Why?
|
| Cells, Cultured | 7 | 2016 | 2154 | 0.120 |
Why?
|
| Lactates | 1 | 2015 | 29 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2015 | 6528 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2015 | 143 | 0.120 |
Why?
|
| Product Recalls and Withdrawals | 1 | 2014 | 1 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2015 | 93 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 44 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 234 | 0.110 |
Why?
|
| Medical Audit | 1 | 2015 | 60 | 0.110 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2015 | 83 | 0.110 |
Why?
|
| Methacrylates | 1 | 2014 | 38 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 220 | 0.110 |
Why?
|
| Alloys | 4 | 2019 | 29 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 108 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 168 | 0.110 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2013 | 42 | 0.100 |
Why?
|
| Joint Diseases | 1 | 1993 | 19 | 0.100 |
Why?
|
| Hip Joint | 1 | 1993 | 35 | 0.100 |
Why?
|
| RANK Ligand | 2 | 2009 | 22 | 0.100 |
Why?
|
| Risk Factors | 4 | 2017 | 5302 | 0.100 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2012 | 30 | 0.100 |
Why?
|
| Program Development | 1 | 2013 | 205 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 416 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 308 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2009 | 889 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 307 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 619 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 1993 | 197 | 0.090 |
Why?
|
| Apatites | 1 | 2011 | 3 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2011 | 49 | 0.090 |
Why?
|
| Logistic Models | 1 | 2015 | 1273 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 133 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2013 | 210 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 517 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2015 | 852 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 2145 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2013 | 179 | 0.090 |
Why?
|
| Cell Proliferation | 5 | 2017 | 981 | 0.090 |
Why?
|
| Self Report | 1 | 2013 | 371 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 583 | 0.090 |
Why?
|
| Data Collection | 1 | 2012 | 384 | 0.090 |
Why?
|
| Communication | 1 | 2015 | 569 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2010 | 28 | 0.090 |
Why?
|
| Pyrazines | 1 | 2010 | 34 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2013 | 355 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2011 | 165 | 0.080 |
Why?
|
| Interleukin-1 | 1 | 2010 | 153 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2017 | 864 | 0.080 |
Why?
|
| Bone Density | 3 | 2015 | 134 | 0.080 |
Why?
|
| Receptors, Leukotriene | 1 | 2009 | 2 | 0.080 |
Why?
|
| Leukotriene Antagonists | 1 | 2009 | 7 | 0.080 |
Why?
|
| Femur Head Necrosis | 1 | 2009 | 3 | 0.080 |
Why?
|
| Wnt Proteins | 2 | 2009 | 98 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 102 | 0.080 |
Why?
|
| Tetracycline | 1 | 2009 | 24 | 0.080 |
Why?
|
| In Vitro Techniques | 4 | 2005 | 487 | 0.080 |
Why?
|
| Elastomers | 1 | 2009 | 7 | 0.080 |
Why?
|
| Algorithms | 1 | 2015 | 1003 | 0.080 |
Why?
|
| Minerals | 1 | 2009 | 20 | 0.080 |
Why?
|
| Bone Remodeling | 1 | 2009 | 25 | 0.080 |
Why?
|
| Tibial Fractures | 1 | 2009 | 13 | 0.080 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2009 | 32 | 0.080 |
Why?
|
| Sterilization | 2 | 2001 | 15 | 0.080 |
Why?
|
| Decision Making | 1 | 2012 | 402 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1540 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2009 | 142 | 0.070 |
Why?
|
| Health Behavior | 1 | 2011 | 466 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2015 | 2039 | 0.070 |
Why?
|
| Equipment Failure Analysis | 2 | 2005 | 75 | 0.070 |
Why?
|
| Calcium | 1 | 2011 | 571 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 520 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2008 | 205 | 0.070 |
Why?
|
| Compressive Strength | 3 | 2013 | 17 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 2173 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 476 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 173 | 0.070 |
Why?
|
| Choristoma | 1 | 1986 | 22 | 0.070 |
Why?
|
| Cell Survival | 3 | 2015 | 573 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2006 | 37 | 0.070 |
Why?
|
| Osseointegration | 2 | 2014 | 5 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2008 | 366 | 0.060 |
Why?
|
| Carrier Proteins | 3 | 2010 | 705 | 0.060 |
Why?
|
| Polymethyl Methacrylate | 1 | 2004 | 14 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 1611 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 212 | 0.050 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 13 | 0.050 |
Why?
|
| Micrococcal Nuclease | 1 | 2023 | 13 | 0.050 |
Why?
|
| Motor Activity | 1 | 2006 | 343 | 0.050 |
Why?
|
| Collagen Type I | 2 | 2017 | 41 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2004 | 497 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2004 | 393 | 0.050 |
Why?
|
| Fractures, Stress | 1 | 2003 | 12 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 933 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 3387 | 0.050 |
Why?
|
| Tissue Engineering | 2 | 2015 | 142 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2006 | 985 | 0.050 |
Why?
|
| Health Status | 1 | 2005 | 433 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2013 | 107 | 0.050 |
Why?
|
| Comorbidity | 1 | 2005 | 1118 | 0.050 |
Why?
|
| Social Support | 1 | 2004 | 370 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1193 | 0.050 |
Why?
|
| Anxiety | 1 | 2004 | 421 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2009 | 3019 | 0.040 |
Why?
|
| Blood Loss, Surgical | 2 | 1997 | 62 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 1991 | 86 | 0.040 |
Why?
|
| Hypertrophy | 2 | 2009 | 30 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2005 | 756 | 0.040 |
Why?
|
| Dalteparin | 1 | 1997 | 2 | 0.040 |
Why?
|
| Thrombophlebitis | 1 | 1997 | 14 | 0.040 |
Why?
|
| Premedication | 1 | 1997 | 16 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2008 | 1528 | 0.040 |
Why?
|
| Depression | 1 | 2004 | 883 | 0.030 |
Why?
|
| Periosteum | 1 | 2017 | 5 | 0.030 |
Why?
|
| Osteophyte | 1 | 2017 | 5 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2017 | 47 | 0.030 |
Why?
|
| Switzerland | 1 | 2017 | 14 | 0.030 |
Why?
|
| Rats, Inbred BB | 1 | 2017 | 134 | 0.030 |
Why?
|
| Cell Line | 2 | 2013 | 2038 | 0.030 |
Why?
|
| Femur Neck | 1 | 1997 | 11 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 78 | 0.030 |
Why?
|
| Incidence | 1 | 2001 | 1367 | 0.030 |
Why?
|
| Bone Plates | 1 | 1997 | 31 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2017 | 51 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 171 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2017 | 185 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2017 | 76 | 0.030 |
Why?
|
| Warfarin | 1 | 1997 | 109 | 0.030 |
Why?
|
| Fracture Fixation, Internal | 1 | 1997 | 59 | 0.030 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2016 | 3 | 0.030 |
Why?
|
| Knee Injuries | 1 | 2016 | 47 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 1997 | 271 | 0.030 |
Why?
|
| Acetabulum | 1 | 2015 | 3 | 0.030 |
Why?
|
| Postoperative Period | 1 | 1995 | 138 | 0.030 |
Why?
|
| Somatomedins | 1 | 1994 | 4 | 0.030 |
Why?
|
| Computer Simulation | 1 | 1997 | 476 | 0.030 |
Why?
|
| Torsion, Mechanical | 1 | 2014 | 4 | 0.030 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 37 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 17 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 25 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 303 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2014 | 7 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 261 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 308 | 0.030 |
Why?
|
| Macrophages | 2 | 2010 | 1039 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2013 | 47 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2013 | 15 | 0.030 |
Why?
|
| Elasticity | 1 | 2013 | 43 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 621 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 35 | 0.030 |
Why?
|
| Anticoagulants | 1 | 1997 | 493 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 1993 | 49 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 178 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2013 | 75 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 115 | 0.030 |
Why?
|
| Amyloid | 1 | 1993 | 68 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2009 | 2097 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 1554 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2011 | 39 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 1139 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 135 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 37 | 0.020 |
Why?
|
| Bortezomib | 1 | 2010 | 56 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2011 | 202 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2010 | 60 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 95 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 189 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 200 | 0.020 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2009 | 9 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2009 | 19 | 0.020 |
Why?
|
| Myoblasts, Skeletal | 1 | 2009 | 12 | 0.020 |
Why?
|
| Sulfides | 1 | 2009 | 22 | 0.020 |
Why?
|
| Bony Callus | 1 | 2009 | 3 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 186 | 0.020 |
Why?
|
| Acetates | 1 | 2009 | 32 | 0.020 |
Why?
|
| Freeze Drying | 1 | 2009 | 14 | 0.020 |
Why?
|
| Quinolines | 1 | 2009 | 42 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2009 | 48 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 208 | 0.020 |
Why?
|
| Powders | 1 | 2009 | 20 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2009 | 49 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 318 | 0.020 |
Why?
|
| Cartilage | 1 | 2009 | 34 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 519 | 0.020 |
Why?
|
| Risk | 2 | 1987 | 375 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 67 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 35 | 0.020 |
Why?
|
| Osteopontin | 1 | 2008 | 21 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 108 | 0.020 |
Why?
|
| Steel | 1 | 2008 | 1 | 0.020 |
Why?
|
| Chromium | 1 | 2008 | 5 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2010 | 256 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2013 | 708 | 0.020 |
Why?
|
| Cobalt | 1 | 2008 | 16 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 152 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2009 | 268 | 0.020 |
Why?
|
| Water | 1 | 2009 | 307 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 1586 | 0.020 |
Why?
|
| Hip | 1 | 1987 | 7 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1986 | 104 | 0.020 |
Why?
|
| SOX9 Transcription Factor | 1 | 2006 | 7 | 0.020 |
Why?
|
| Collagen Type X | 1 | 2006 | 4 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2006 | 12 | 0.020 |
Why?
|
| Growth Plate | 1 | 2006 | 9 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2006 | 24 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 1451 | 0.020 |
Why?
|
| beta Catenin | 1 | 2006 | 93 | 0.020 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2006 | 142 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2006 | 111 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1986 | 125 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 660 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 544 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2006 | 610 | 0.010 |
Why?
|
| Pressure | 1 | 2005 | 77 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 794 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2006 | 392 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2006 | 310 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 937 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1180 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 888 | 0.010 |
Why?
|
| Biomarkers | 1 | 2008 | 1382 | 0.010 |
Why?
|
| Motion | 1 | 2003 | 59 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 761 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 637 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 335 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 250 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 400 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 1638 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 1508 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1997 | 266 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 1994 | 7 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1994 | 24 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1994 | 63 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1994 | 42 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1994 | 53 | 0.010 |
Why?
|
| Bone Diseases, Metabolic | 1 | 1994 | 20 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1994 | 188 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 1994 | 76 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 231 | 0.010 |
Why?
|
| Rabbits | 1 | 1994 | 332 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 455 | 0.010 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 1987 | 1 | 0.000 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1987 | 24 | 0.000 |
Why?
|